← Back to Search

Metal Chelator

Inhaled AR-501 for Cystic Fibrosis

Phase 1 & 2
Recruiting
Research Sponsored by Aridis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Written informed consent given by the subject.
At least ≥ 18 years old and < 50 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days following dose administration
Awards & highlights

Study Summary

This trial will study the safety and effectiveness of inhaled AR-501 to treat P. aeruginosa-infected cystic fibrosis in healthy adults.

Eligible Conditions
  • Cystic Fibrosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days following dose administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days following dose administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical safety profile (adverse events) - Multiple Ascending Dose
Clinical safety profile (adverse events) - Single Ascending Dose
Secondary outcome measures
Pharmacokinetics (PK) Profile - MAD AUC0-inf
Pharmacokinetics (PK) Profile - MAD AUC0-last
Pharmacokinetics (PK) Profile - MAD Clp
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AR-501 inhaledExperimental Treatment1 Intervention
Four doses (low, medium, high, top) of inhaled AR-501 will be used.
Group II: inhaled AR-501 PlaceboPlacebo Group1 Intervention
Four doses (low, medium, high, top) of inhaled placebo will be used

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Aridis Pharmaceuticals, Inc.Lead Sponsor
5 Previous Clinical Trials
960 Total Patients Enrolled
Hasan S Jafri, MD, FAAPStudy DirectorAridis Pharmaceuticals, Inc.
1 Previous Clinical Trials
174 Total Patients Enrolled
Alan H Cohen, MDStudy DirectorAridis Pharmaceuticals, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~16 spots leftby Mar 2025